AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16232173 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=43)
Number of subjects: 120
Study 16232173 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=29)
Number of subjects: 120
Study 10321674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (5 mg/kg/hr for 6 hrs on 6 successive days)
Number of subjects: 100
Study 10321674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 100
Study 10321674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8846875 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal loop colostomy
Number of subjects: 16
Study 8846875 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional terminal colostomy (TA 55 stapler)
Number of subjects: 16
Study 2018406 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall periods ranging from 'the past 3 days' to 'the past year' and 'usual intake' (Study 1 and 2)
Number of subjects: 232
Study 2018406 — intervention group
Group type: EXPERIMENTAL
Intervention: Short recall periods (e.g., last weekend, the past 5 days) (Study 3)
Number of subjects: 232
Study 7057164 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instruction group (n = 10)
Number of subjects: 29
Study 7057164 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control (n = 9)
Number of subjects: 29
Study 7057164 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 29
Study 31590139 — intervention group
Group type: EXPERIMENTAL
Intervention: ALERTA ALCOHOL intervention
Number of subjects: 1247
Study 31590139 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1247
Study 29590436 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Care Management (ACM)
Number of subjects: 163
Study 29590436 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 163
Study 26679977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasally inhaled isopropyl alcohol
Number of subjects: 84
Study 26679977 — intervention group
Group type: COMPARATOR
Intervention: Nasally inhaled normal saline solution (placebo)
Number of subjects: 84
Study 24845609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg, 3 times daily)
Number of subjects: 121
Study 24845609 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (40 mg daily)
Number of subjects: 121
Study 22194371 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior vertebral arch cement augmentation (spinoplasty)
Number of subjects: 35
Study 22194371 — intervention group
Group type: COMPARATOR
Intervention: No spinoplasty (control group)
Number of subjects: 35
Study 20640997 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 30
Study 20640997 — intervention group
Group type: COMPARATOR
Intervention: Conventional techniques (CT)
Number of subjects: 30
Study 19063731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin therapy (10 ml/kg over 4-6 hours, repeated 48 hours later)
Number of subjects: 0
Study 19063731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15652873 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone treatment
Number of subjects: 44
Study 15652873 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment
Number of subjects: 44
Study 15652873 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 44
Study 11818199 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral UFT 300 mg/m2/day plus oral LV 90 mg/day for 28 days every 5 weeks
Number of subjects: 37
Study 11818199 — intervention group
Group type: COMPARATOR
Intervention: i.v. 5‐FU 425 mg/m2/day plus LV 20 mg/m2/day for 5 days every 4 weeks
Number of subjects: 37
Study 11818199 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral UFT
Number of subjects: 37
Study 11818199 — intervention group
Group type: COMPARATOR
Intervention: i.v. 5‐FU
Number of subjects: 37
Study 10743481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Number of subjects: 11
Study 10743481 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose with first meal
Number of subjects: 11
Study 10743481 — intervention group
Group type: COMPARATOR
Intervention: Rapeseed oil, Sunflower oil, Palm oil
Number of subjects: 11
Study 8820252 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg capsules)
Number of subjects: 18
Study 8820252 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 18
Study 30907143 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Independence Measure (FIM)
Number of subjects: 3506
Study 30907143 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D-3L
Number of subjects: 3506
Study 31423755 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion strength training at short muscle length
Number of subjects: 12
Study 31423755 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee flexion strength training at optimal muscle length
Number of subjects: 12
Study 28645291 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg intravenous infusion)
Number of subjects: 39
Study 28645291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 25510286 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fish oil supplementation
Number of subjects: 562
Study 25510286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562
Study 25510286 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP
Number of subjects: 562
Study 25510286 — intervention group
Group type: EXPERIMENTAL
Intervention: hs‐cTnT
Number of subjects: 562
Study 25510286 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP and hs‐cTnT levels
Number of subjects: 562
Study 23623849 — intervention group
Group type: EXPERIMENTAL
Intervention: NS1209
Number of subjects: 28
Study 23623849 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin/Valproate (third-line standard treatment)
Number of subjects: 28
Study 21823043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-30 mg/day)
Number of subjects: 68
Study 21823043 — intervention group
Group type: COMPARATOR
Intervention: Metformin (500-750 mg/day)
Number of subjects: 68
Study 19318433 — intervention group
Group type: EXPERIMENTAL
Intervention: MMS19L genotype (chromosome 10q24.1)
Number of subjects: 1143
Study 19318433 — intervention group
Group type: EXPERIMENTAL
Intervention: Haplotype analysis of MMS19L
Number of subjects: 1143
Study 19318433 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven individual SNPs in MMS19L
Number of subjects: 1143
Study 16413335 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar plasmakinetic TURP (Gyrus device)
Number of subjects: 70
Study 16413335 — intervention group
Group type: COMPARATOR
Intervention: Standard monopolar TURP
Number of subjects: 70
Study 15720808 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with 5-FU
Number of subjects: 166
Study 15720808 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant chemotherapy
Number of subjects: 166
Study 11401110 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (EPO) and intravenous (IV) iron
Number of subjects: 32
Study 11401110 — intervention group
Group type: COMPARATOR
Intervention: Not treated (Control Group B)
Number of subjects: 32
Study 9424006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated XRT (total dose 69.60‐76.80 Gy, 1.2 Gy b.i.d. five times a week) combined with superficial external HT (2 to 6 sessions)
Number of subjects: 27
Study 8499097 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms/d of misoprostol, increased every 5 days by 200 micrograms until a total of 800 micrograms/d was achieved
Number of subjects: 24
Study 8499097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3800150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine methonitrate (AM) 125 micrograms 3 times a day for 5 days
Number of subjects: 34
Study 3800150 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine methonitrate (AM) 250 micrograms 4 times a day for 5 days
Number of subjects: 34
Study 3800150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 34
Study 31723017 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth prompt about care breakdowns
Number of subjects: 1188
Study 31723017 — intervention group
Group type: EXPERIMENTAL
Intervention: Full apology
Number of subjects: 1188
Study 31723017 — intervention group
Group type: COMPARATOR
Intervention: No prompt
Number of subjects: 1188
Study 31723017 — intervention group
Group type: COMPARATOR
Intervention: No apology
Number of subjects: 1188
Study 31519279 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction (MBSR)
Number of subjects: 127
Study 31519279 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 127
Study 28173775 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance program (highly challenging balance training) provided by physical therapists as part of standard rehabilitation care.
Number of subjects: 0
Study 28173775 — intervention group
Group type: EXPERIMENTAL
Intervention: HiBalance program (highly challenging balance training)
Number of subjects: 0
Study 24921211 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole, Amoxicillin, and Clarithromycin (RAC)
Number of subjects: 124
Study 24921211 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole, Amoxicillin, and Metronidazole (RAM)
Number of subjects: 124
Study 23627960 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22091740 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICSs)
Number of subjects: 125
Study 22091740 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids
Number of subjects: 125
Study 22091740 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting β‐agonist
Number of subjects: 125
Study 19071883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen sodium 200 mg
Number of subjects: 10
Study 19071883 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 10
Study 19071883 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg
Number of subjects: 10
Study 19071883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen sodium
Number of subjects: 10
Study 16874795 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee OA pain assessment using visual analog scale; Knee OA function assessment using Western Ontario and McMaster Universities Osteoarthritis Index function subscale.
Number of subjects: 1290
Study 16874795 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute RCS pain assessment using numeral rating scale; RCS function assessment using Neer function subscale.
Number of subjects: 1290
Study 16874795 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional impairment assessment for knee OA.
Number of subjects: 1290
Study 12893645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose house dust mite allergen exposure
Number of subjects: 36
Study 12893645 — intervention group
Group type: EXPERIMENTAL
Intervention: RV16 infection
Number of subjects: 36
Study 10883566 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk intervention group
Number of subjects: 153
Study 10883566 — intervention group
Group type: COMPARATOR
Intervention: High-risk control group
Number of subjects: 153
Study 10883566 — intervention group
Group type: COMPARATOR
Intervention: Functional comparison group
Number of subjects: 153
Study 9012701 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum oncostatin M (OSM) levels in OSM+ patients
Number of subjects: 40
Study 9012701 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL‐6 levels
Number of subjects: 40
Study 9012701 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum C‐reactive protein (CRP) levels
Number of subjects: 40
Study 9012701 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta 2M concentration
Number of subjects: 40
Study 9012701 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sIL‐6R levels
Number of subjects: 40
Study 9012701 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical data (age, gender, myeloma protein or stage)
Number of subjects: 40
Study 8268899 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily
Number of subjects: 4396
Study 8268899 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tablet containing hydrochlorothiazide 25 mg and amiloride 2.5 mg
Number of subjects: 4396
Study 8268899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4396
Study 2880460 — intervention group
Group type: EXPERIMENTAL
Intervention: Procyclidine, Orphenadrine, Trihexyphenidyl hydrochloride (1/3 DDD)
Number of subjects: 7
Study 2880460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29400921 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg once daily for up to 28 days
Number of subjects: 540
Study 29400921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study 28251654 — intervention group
Group type: EXPERIMENTAL
Intervention: BGCC (3 g d-1) for 12 weeks
Number of subjects: 56
Study 28251654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 25677127 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation intervention
Number of subjects: 315
Study 25677127 — intervention group
Group type: COMPARATOR
Intervention: Information provision (control)
Number of subjects: 315
Study 22863840 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 181
Study 22863840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study 21492347 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Learning (BL)
Number of subjects: 90
Study 21492347 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-Face Learning (F2FL)
Number of subjects: 90
Study 21492347 — intervention group
Group type: EXPERIMENTAL
Intervention: E-learning (EL)
Number of subjects: 90
Study 19738017 — intervention group
Group type: EXPERIMENTAL
Intervention: n-propanol 89.5% for 2 min application
Number of subjects: 180
Study 19738017 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol and isopropanol
Number of subjects: 180
Study 19738017 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol supplemented with 0.5% or more chlorhexidine digluconate (CHG)
Number of subjects: 180
Study 19738017 — intervention group
Group type: EXPERIMENTAL
Intervention: n-propanol 89.5%
Number of subjects: 180
Study 19738017 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of n-propanol with CHG
Number of subjects: 180
Study 19738017 — intervention group
Group type: COMPARATOR
Intervention: 0.5%, 1%, or 2% chlorhexidine digluconate (CHG) in 89.5% n-propanol
Number of subjects: 180
Study 16368077 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone/corticotropin-releasing hormone (DEX/CRH) test after 8 weeks of antidepressant treatment
Number of subjects: 45
Study 16368077 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher posttreatment maximal cortisol response on the DEX/CRH test
Number of subjects: 45
Study 15270974 — intervention group
Group type: EXPERIMENTAL
Intervention: Frova single-use introducer
Number of subjects: 48
Study 15270974 — intervention group
Group type: EXPERIMENTAL
Intervention: Eschmann multiple-use introducer
Number of subjects: 48
Study 15270974 — intervention group
Group type: COMPARATOR
Intervention: Portex single-use introducer
Number of subjects: 48
Study 15270974 — intervention group
Group type: EXPERIMENTAL
Intervention: Frova and Portex introducers
Number of subjects: 48
Study 12143474 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Start program (intervention group)
Number of subjects: 0
Study 12143474 — intervention group
Group type: COMPARATOR
Intervention: No participation in the Healthy Start program (control group)
Number of subjects: 0
Study 9489938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 12
Study 9489938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 9489938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9489938 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg and 10 mg)
Number of subjects: 12
Study 7996118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (KT) 60 mg to 2 ml
Number of subjects: 40
Study 7996118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride, 0.9%)
Number of subjects: 40
Study 2725404 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 103
Study 2725404 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 103
Study 5411599 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 71
Study 5411599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate
Number of subjects: 71
Study 5411599 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone acetate plus saline
Number of subjects: 71
Study 31778291 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified exercise therapy (subgroup-specific protocolized exercise therapy, with dietary intervention for obesity subgroup)
Number of subjects: 408
Study 31778291 — intervention group
Group type: COMPARATOR
Intervention: Usual care by physical therapists (nonstratified exercise therapy)
Number of subjects: 408
Study 28502744 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sodium selenite (4000 μg IV after induction, 1000 μg/d during ICU stay)
Number of subjects: 411
Study 28502744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 27608768 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted remote consultations at a regional medical centre (RMC)
Number of subjects: 400
Study 27608768 — intervention group
Group type: COMPARATOR
Intervention: Standard consultation in the orthopaedic outpatient clinic at the University Hospital of North Norway (UNN)
Number of subjects: 400
Study 27608768 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted consultations
Number of subjects: 400
Study 27608768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancillary analyses
Number of subjects: 400
Study 25142039 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (5 to 20 mg/day; n=20)
Number of subjects: 40
Study 25142039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study 23283817 — intervention group
Group type: EXPERIMENTAL
Intervention: GIST patients (n=15)
Number of subjects: 45
Study 23283817 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 45
Study 20334585 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitex agnus castus (VAC, BNO 1095)
Number of subjects: 67
Study 20334585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 18684057 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (Ontak®)
Number of subjects: 0
Study 16567324 — intervention group
Group type: COMPARATOR
Intervention: Placebo responders
Number of subjects: 904
Study 12760700 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface-penetrating sealant (Protect‐it!‐PI)
Number of subjects: 30
Study 12760700 — intervention group
Group type: EXPERIMENTAL
Intervention: One bottle adhesive system (Single Bond‐SB)
Number of subjects: 30
Study 12760700 — intervention group
Group type: COMPARATOR
Intervention: Non-sealed control
Number of subjects: 30
Study 10757577 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine (80 mg, 20 mg/ml)
Number of subjects: 100
Study 10757577 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (80 mg, 20 mg/ml)
Number of subjects: 100
Study 1591947 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (50 mg orally 4 times a day)
Number of subjects: 198
Study 1591947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl sulphoxide (DMSO, 500 mg orally 4 times a day)
Number of subjects: 198
Study 1591947 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 198
Study 2413292 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 28
Study 2413292 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 28
Study 30715378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological and non-pharmacological interventions for CIPN
Number of subjects: 0
Study 29331384 — intervention group
Group type: EXPERIMENTAL
Intervention: Different feedback delivery methods (specific methods not detailed)
Number of subjects: 500
Study 29331384 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 500
Study 29331384 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 500
Study 29331384 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback accuracy (specific accuracy levels not detailed)
Number of subjects: 500
Study 26414317 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise regional circulatory occlusion (RCO) for 2-min recovery
Number of subjects: 11
Study 26414317 — intervention group
Group type: COMPARATOR
Intervention: Normal recovery (NR)
Number of subjects: 11
Study 26414317 — intervention group
Group type: EXPERIMENTAL
Intervention: RCO + CO2
Number of subjects: 11
Study 26414317 — intervention group
Group type: COMPARATOR
Intervention: Control trial (NR)
Number of subjects: 11
Study 25455006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 33557
Study 25455006 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 33557
Study 25455006 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 33557
Study 23506685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating red, green and blue light exposure
Number of subjects: 20
Study 20979471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Number of subjects: 210
Study 18071721 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg
Number of subjects: 292
Study 18071721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 15721217 — intervention group
Group type: EXPERIMENTAL
Intervention: Left rTMS
Number of subjects: 39